Sporanox and Lamisil
Public Health Advisory
The FDA issued a Public Health Advisory to announce important
safety-related updates to the labeling of Sporanox® (itraconazole) and
Lamisil® (terbinafine hydrochloride) Tablets.
FDA is advising healthcare professionals not to prescribe Sporanox® to
treat fungal infections (onychomycosis) in patients who have congestive
heart failure (CHF) or a history of CHF. The updated Sporanox® labeling
also includes contraindications and precautions with certain medicines.
Back to Top
Drug Information
FDA/Center for Drug Evaluation and Research
Last Updated: May 14, 2001
Originator: OTCOM/DLIS
HTML by PKS |